Results: A total of 150 patients with gram-positive osteomyelitis were treated with ceftaroline fosamil. Most patients (78.0%) were treated with 600 mg; 95.3% received a dose every 12 hours. The majority (89 [59.3%]) had been previously diagnosed with diabetes mellitus or peripheral vascular disease. Osteomyelitis was associated with hardware in 32 (21.3%) patients. Methicillin-resistant and methicillin-susceptible Staphylococcus aureus(MRSA; MSSA) were the most commonly isolated pathogens, observed in 93 (62.0%) and 21 (14.0%) patients, respectively. Clinical success with ceftaroline fosamil therapy was observed in 139/150 (92.7%) patients overall, 81/89 (91.0%) patients with diabetes or peripheral vascular disease, and 18/20 (90.0%) patients who had hardware implanted before ceftaroline fosamil therapy (none had hardware removed during therapy). Patients who received prior antibiotic therapy or ceftaroline fosamil as monotherapy experienced clinical success rates of 93.9% (107/114) and 91% (91/100), respectively. Among patients who received concurrent antibiotic therapy, the clinical success rate was 96.0% (48/50). Patients who were infected with MRSA or MSSA had clinical success rates of 92.5% (86/93) and 100% (21/21), respectively. A total of 2 (1.3%) patients discontinued ceftaroline fosamil therapy because of adverse events.
L. B. Johnson,
A. Ramani, Allergan: Speaker's Bureau , Speaker honorarium
Gilead: Speaker's Bureau , Speaker honorarium
D. Guervil, None
See more of: Poster Abstract Session